Literature DB >> 26479766

Age-Dependent Seroprevalence of JCV Antibody in Children.

Eva Maria Hennes1, Barbara Kornek2, Peter Huppke3, Markus Reindl4, Kevin Rostasy5, Thomas Berger4.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is an opportunistic central nervous system infection, caused by the John Cunningham virus (JCV). PML may occur during treatment with immunosuppressive agents or monoclonal antibodies such as natalizumab. The JCV seroprevalence increases with age with a seropositivity of 60% in the adult human population. In this study, we analyzed sera from 109 pediatric multiple sclerosis (MS) patients (mean age 14 years) as well as sera from 162 patients with a wide range of suspected neurologic disorders (mean age 6.3 years). Our results showed a considerably lower seroprevalence for JCV in our pediatric cohort with 33.3% and equal distribution in both subgroups, compared with reported seropositivity in adult population. This could result in a lower risk for drug-induced PML in pediatric patients compared with adult patients and can influence the indication for natalizumab therapy in pediatric MS patients. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26479766     DOI: 10.1055/s-0035-1565272

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  8 in total

Review 1.  Atypical Pediatric Demyelinating Diseases of the Central Nervous System.

Authors:  Regina M Troxell; Alison Christy
Journal:  Curr Neurol Neurosci Rep       Date:  2019-11-26       Impact factor: 5.081

2.  Natalizumab therapy in patients with pediatric-onset multiple sclerosis in Greece: clinical and immunological insights of time-long administration and future directions-a single-center retrospective observational study.

Authors:  Maria Gontika; Charalampos Skarlis; Nikolaos Markoglou; Dimitrios Tzanetakos; Aglaia Vakrakou; Panagiotis Toulas; George Koutsis; Maria-Eleptheria Evangelopoulos; Roser Pons; Efthymios Dardiotis; George Chrousos; Marinos Dalakas; Leonidas Stefanis; Maria Anagnostouli
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-04-26       Impact factor: 3.195

Review 3.  Bringing the HEET: The Argument for High-Efficacy Early Treatment for Pediatric-Onset Multiple Sclerosis.

Authors:  Marisa McGinley; Ian T Rossman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 4.  Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.

Authors:  Elizabeth A Mills; Yang Mao-Draayer
Journal:  Mult Scler       Date:  2018-05-18       Impact factor: 6.312

5.  Antibody response to polyomavirus primary infection: high seroprevalence of Merkel cell polyomavirus and lymphoid tissue involvement.

Authors:  Carolina Cason; Lorenzo Monasta; Nunzia Zanotta; Giuseppina Campisciano; Iva Maestri; Massimo Tommasino; Michael Pawlita; Sonia Villani; Manola Comar; Serena Delbue
Journal:  J Neurovirol       Date:  2018-01-12       Impact factor: 2.643

Review 6.  Paediatric Multiple Sclerosis: Update on Diagnostic Criteria, Imaging, Histopathology and Treatment Choices.

Authors:  I-Jun Chou; Huei-Shyong Wang; William P Whitehouse; Cris S Constantinescu
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

7.  Database and Statistical Analyses of Transcription Factor Binding Sites in the Non-Coding Control Region of JC Virus.

Authors:  Kazuo Nakamichi; Toshio Shimokawa
Journal:  Viruses       Date:  2021-11-19       Impact factor: 5.048

Review 8.  Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease.

Authors:  Irene Cortese; Daniel S Reich; Avindra Nath
Journal:  Nat Rev Neurol       Date:  2020-11-20       Impact factor: 42.937

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.